Journal Guide

International Journal of Gynecological Cancer presents papers from throughout the global community of researchers covering many topics including:basic science epidemiology diagnostic techniques surgery radiotherapy chemotherapy pathology experimental studies The Journal allows you to call on a roster of international experts for the latest research, advice, and knowledge in order to provide the best treatment for your patients. The list of editorial board members represents every part of the globe and all the major disciplines - gynecology, oncology, radiation therapy, and pathology - involved in treating cancer. Let the International Journal of Gynecological Cancer bring the world's best research to you nine times a year in a concise and easy-to-read format.

* Biological Abstracts® (Thomson ISI) * BIOSIS Previews® (Thomson ISI) * Biotechnology & Bioengineering Abstracts (CSA/CIG) * Biowizard (Biowizard) * CAB Abstracts® (CABI) * Cambridge Scientific Abstracts (CSA/CIG) * Chemical Abstracts Service/SciFinder (ACS) * CSA Biological Sciences Database (CSA/CIG) * CSA Environmental Sciences & Pollution Management Database (CSA/CIG) * Current Awareness in Biological Sciences (Elsevier) * Current Contents®/Life Sciences (Thomson ISI) * EMBASE/Excerpta Medica (Elsevier) * Google Scholar * Index Copernicus (IC) * Index Medicus/MEDLINE/PubMed (NLM) * Journal Citation Reports/Science Edition (Thomson ISI) * PASCAL Database (INIST/CNRS) * Reference Update (Thomson ISI) * Science Citation Index Expanded™ (Thomson ISI) * Science Citation Index® (Thomson ISI) * SCOPUS (Elsevier) * Web of Science (Thomson ISI).

International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.The Red Journal's sister publication is Practical Radiation Oncology. Click here to see which types of papers these journals typically accept.

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

Investigatio

JAMA Oncology is the definitive journal for scientists, clinicians and trainees in the field of oncolgy worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenisis and recent treatment advances for our readers. JAMA oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

JMIR Cancer (JC) is a Pubmed- and ESCI-indexed, peer-reviewed journal with a focus on education, innovation and technology in cancer care, cancer survivorship and cancer research, as well as in participatory and patient-centred approaches. This journal also includes research on non-Internet approaches to improve cancer care and cancer research.

Manuscripts from key conferences dealing with cancer and closely related research fields, or a related group of papers on specific subjects of importance to cancer research, are considered for publication, with the understanding that they have not been published previously and are submitted exclusively to the Journal of the National Cancer Institute Monographs. All material submitted for consideration will be subject to review, when appropriate, by at least one outside reviewer and one member of the Editorial Board of the Journal of the National Cancer Institute. Opinions expressed by authors are not necessarily those of the publisher or the editors.

Japanese Journal of Clinical Oncology is a multidisciplinary journal for clinical oncologists which strives to publish high quality manuscripts addressing medical oncology, clinical trials, radiology, surgery, basic research, and palliative care. The journal aims to contribute to the world’s scientific community with special attention to the area of clinical oncology and the Asian region.JJCO publishes various articles types including:*Original Articles*Case Reports*Clinical Trial Notes*Cancer Genetics Reports*Epidemiology Notes*Technical Notes*Short Communications*Letters to the Editors*Solicited ReviewsThe journal also welcomes interim articles on the design and plan of phase studies before actual results are obtained. While clinical trials usually require a long time to accomplish a conclusive outcome, the journal believes reports of interim outcomes will be highly appreciated by its audience. .

Journal for ImmunoTherapy of Cancer is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.The journal welcomes submissions in the following areas and other related topics:Basic Tumor ImmunologyTumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune responseClinical/Translational Cancer ImmunotherapyFirst-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcomeImmunotherapy BiomarkersPredictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studiesReviews/EditorialsTriggering discussion on hot topics and innovative concepts

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The society has become THE forum for innovative discussions in the field.